Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00203775
NCT00203775TerminatedNot Applicable

Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates

University of Connecticut1 site in 1 countryStarted: July 1, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study examines the efficacy of haldol versus risperdal in the treatment of aggression in psychotic prison inmates. It is hypothsized that risperdal will be more effective in decreasing aggression than haldol.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •age 18 or over, psychotic disorder diagnosed on SCID, inmate at correctional facility for at least 2 weeks -

Exclusion Criteria

  • •active withdrawal from substances of abuse, non-psychotic individuals, pregnant women, people unable to give informed consent, patients on mood stabilizers

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaPsychotic DisordersSchizophrenia
NCT00249132Janssen, LP523
Completed
Phase 4
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective DisorderSchizophreniaSchizoaffective Disorder
NCT00253110Janssen, LP396
Completed
Not Applicable
Haloperidol and Risperidone efficacy for Attention Deficit Hyperactivity Disorder treatmentAttention deficit hyperactivity disorder.hyperkinetic disorder
IRCT2015082623766N1vice chancellor for research of Ahwaz Jondishapour University of Medical Sciences46
Completed
Phase 3
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaAlzheimer DiseaseVascular DementiaDementia
NCT00249158Janssen-Cilag Pty Ltd344
Completed
Phase 4
Oral Versus Injectable Risperidone for Treating First-Episode SchizophreniaSchizophrenia
NCT00330551University of California, Los Angeles126